Circulation
Articles in this Issue
Abstract 4366999: Optimizing Representation and Retention in Hybrid Cardiac Rehabilitation: Lessons Learned from the mTECH-Rehab Randomized Controlled Trial
Background: Cardiac rehab (CR) is a critical but underused secondary prevention program. Hybrid CR programs have the potential to improve patient access by enabling home CR session...
Abstract 4345655: Sodium–Glucose Cotransporter 2 Inhibitors are Cost-Effective and Dominate Glucagon-Like Peptide-1 Receptor Agonists for Patients with Type 2 Diabetes and High Cardiorenal Risk in Canada
Background: The Canadian Cardiovascular Society recommends that patients with type 2 diabetes (T2D) and cardiovascular disease, renal disease, or multiple cardiovascular risk facto...
Abstract 4352628: Time-Sensitive Cardiovascular Risk After COVID-19: A Population-Based Study Across Variant Eras
Introduction: Cardiovascular risks following SARS-CoV-2 infection are incompletely defined. We evaluated evolving cardiovascular outcomes across COVID-19 variant eras using a large...
Abstract 4367530: Impact Of Admission Timing On Management And In-Hospital Outcomes In Acute Heart Failure: Insight From The CAN-HF Registry
Background: The impact of hospital admission timing on outcomes in acute heart failure (AHF) remain unclear. Prior studies suggest that timing of hospital presentation may affect e...
Abstract 4363608: Reversal of Decline in Premature Cardiac Arrest Mortality: Demographic and Regional Trends in the United States, 1999–2021
Background: Premature cardiac arrest (CA) is a major cause of death under 65. While declines in CA-related mortality have been observed, national, demographic, and regional trends...
Abstract 4362959: Redox Mediated Dysregulation of Sarcomere Proteins Impairs Cardiac Relaxation in a Murine Model of Preeclampsia
Introduction: Preeclampsia (PE), a leading cause of maternal morbidity and mortality, is associated with diastolic dysfunction and increased long-term cardiovascular risk. Mice lac...
Abstract 4368897: Albuminuria Drives Type 2 Diabetes-Related Atrial Fibrillation: an ACCORD substudy
Background: Patients with type 2 diabetes (T2D) are at elevated risk for atrial fibrillation (AF), potentially driven by glycemic variability, oxidative stress, and inflammation-in...
Abstract 4366551: Cardiac Allograft Vasculopathy Involves Vascular Remodeling Beyond the Coronary Arteries
Background: Cardiac allograft vasculopathy (CAV) is the leading cause of morbidity and mortality one-year post heart transplant. It is characterized by diffuse neointimal thickenin...
Abstract 4364340: Survivors of Childhood Cancers Exposed to Cardiotoxic Therapies Demonstrate Diastolic Dysfunction by Cardiac MRI
Introduction/Background: Toxicity from cancer therapy is a leading cause of morbidity and mortality in childhood cancer survivors (CCS). Research in the cardiotoxic effects of canc...
Abstract 4353911: In-Hospital, 1-Year and 5-Year Clinical Outcomes of Patients With Severe Aortic Stenosis Treated With Transcatheter Aortic Valve Replacement and Sodium-Glucose Cotransporter 2 Inhibitors
Background: Recent studies have demonstrated that sodium-glucose cotransporter 2 inhibitors (SGLT2i) may reduce procedure-related acute kidney injury (AKI), heart failure readmissi...
Abstract 4365647: Prediction of Mortality and Morbidity After Acute Myocardial Infarction Using Medication-Enriched Real-World Clinical Data and Machine Learning
Background: Despite advances in acute myocardial infarction (AMI) management, long-term risks such as cardiovascular mortality, recurrent AMI, and heart failure remain substantial....
Abstract 4371556: Reassessing the Blanking Period: Early Recurrence as a Predictor of Late Atrial Fibrillation Recurrence After Pulsed Field Ablation
Background: A blanking period allowing for atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI) has historically been standardized to 90 days. With the recent i...
Abstract 4368707: Female Patients Receive Appropriate Implantable Defibrillator Therapy at a Rate Close to That of Males: Analysis of a 10-year Contemporary Cohort
Background: Implantable cardioverter-defibrillators (ICDs) are a proven therapy for reducing mortality in patients at risk for ventricular arrhythmias that can lead to sudden cardi...
Abstract 4360601: Body Mass Index, Diastolic Blood Pressure, and Hypertrophic Cardiomyopathy Polygenic Background Differentially Modify Hypertrophic Cardiomyopathy Risk
Background: Hypertrophic cardiomyopathy (HCM) risk is incompletely explained by pathogenic variants and polygenic background. Mendelian randomization studies have implicated body m...
Abstract 4370201: Heart of the Matter: Quantifying Fibrosis by LGE-CMR to Predict Sudden Death in Hypertrophic Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) is a common genetic heart condition with a variable risk of sudden cardiac death (SCD) and heart failure. Late gadolinium enhancement...
Abstract 4350994: Transcatheter Aortic Valve Replacement with Percutaneous Coronary Intervention vs Surgical Aortic Valve Replacement with Coronary Artery Bypass Graft in Aortic Stenosis and Coronary Disease: An updated Systematic Review and Meta Analysis
Background: Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist, often requiring both valve replacement and coronary revascularization. While surgical aortic...
Abstract 4361293: Anxiety Disorder as an Independent Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-Analysis
Background: Anxiety disorders are common, but their role in cardiovascular risk is underrecognized. Traditional risk factors for coronary heart disease (CHD), such as hypertension...
Abstract 4363340: Target Product Profile to Evaluate the Clinical Utility, Financial Impact, and Ethical Implications of an AI-Based HCM Detection Model
Hypertrophic cardiomyopathy (HCM) remains underdiagnosed despite effective therapies and accessible screening with electrocardiogram (ECG) and echocardiography. Multiple artificial intelligence (AI) t...
Abstract 4368556: Mechanical Circulatory Support Device Related Complications in Contemporary North American Cardiac Intensive Care Units
Background: The use of temporary mechanical circulatory support (tMCS) devices in cardiogenic shock has sharply risen; however, there are limited data depicting the current rates o...
Abstract 4366252: UPDATED OUTCOMES OF ADULTS WITH CONGENITAL HEART DISEASE AND HETEROTAXY
Introduction: Heterotaxy syndrome (HS) manifests in varying degrees, involving abnormal left and right thoraco-abdominal organ distribution and frequently associated with congenita...
Abstract 4348028: Association of Remnant Cholesterol with Prevalent Cardiovascular Disease in Individuals With and Without Diabetes: A Cross-Sectional Analysis of NHANES 2005–2018
Background: Both diabetes and dyslipidemia are well-established risk factors for cardiovascular disease (CVD). However, traditional lipid measures do not fully explain the excess C...
Abstract 4368263: Use of Contemporary Cardiometabolic Therapies in Cardiac Amyloidosis Treated with Tafamidis: A Real-World Propensity-Matched Analysis
Background: Tafamidis is the standard therapy for transthyretin cardiac amyloidosis, but the role of adjunctive medications such as SGLT2 inhibitors, mineralocorticoid receptor ant...
Abstract 4371653: Racial Differences in Right Ventricular Load Adaptation: Pulmonary Arterial Compliance and RV Stroke Work Index in Right Heart Catheterization and Transthoracic ECHO
Introduction: Racial disparities significantly influence cardiovascular outcomes, particularly in pulmonary hypertension (PH). African American (AA) patients often demonstrate dist...
Abstract 4371137: Mechanisms of Heart Failure Induced by Myofilament Mutations: Disruption of mRNA Stability and Expression?
Background: mRNA modification and degradation can reduce expression of protein leading to heart failure. Cardiac myosin binding protein-C (cMyBPC) with gene (MyBPC3) is a thick fil...
Abstract 4369118: Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)
Background: In the SELECT trial, semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease...